{"success":true,"data":{"pressRelease":{"id":"31488","rtpr_id":"nPn9WFT6Ka","ticker":"ISPR","exchange":"NASDAQ","all_tickers":["ISPR"],"title":"Ispire Technology Expands Into High-Growth Nicotine Pouch Market Through Strategic Joint Venture with Jincheng Pharma","author":"PR Newswire","published_at":"2026-05-12T12:30:02.562Z","article_body":"Ispire Technology Expands Into High-Growth Nicotine Pouch Market Through Strategic Joint Venture with Jincheng Pharma\n\nPR Newswire\n\nLOS ANGELES, May 12, 2026\n\nPartnership combines pharmaceutical-grade manufacturing with Ispire's global\nplatform to accelerate entry into one of the fastest-growing nicotine segments\n\nLOS ANGELES, May 12, 2026 /PRNewswire/ -- Ispire Technology Inc.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4685825-1&h=609010424&u=https%3A%2F%2Fispiretechnology.com%2F&a=Ispire+Technology+Inc.)\n(\"Ispire\" or the \"Company\") (NASDAQ: ISPR\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4685825-1&h=3905662850&u=https%3A%2F%2Fwww.nasdaq.com%2Fmarket-activity%2Fstocks%2Fispr&a=NASDAQ%3A+ISPR)\n), a trailblazer in vaping technology and precision dosing, announced that it\nhas entered into a joint venture with Shandong Jincheng Pharmaceutical Group\nCo., Ltd.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4685825-1&h=3130007742&u=http%3A%2F%2Fwww.jinchengpharm.com%2Fwap_index_en.html&a=Shandong+Jincheng+Pharmaceutical+Group+Co.%2C+Ltd.)\n(SZSE: 300233) (\"Jincheng Pharma\"), a global pharmaceutical company, to\nmanufacture and commercialize nicotine pouch products.\n\n(https://mma.prnewswire.com/media/2771569/Ispire_Technology_Logo.html)\n\nThe joint venture marks Ispire's entry into the rapidly expanding oral\nnicotine category, broadening its portfolio beyond vaping hardware and\npositioning the Company in one of the fastest-growing segments of the global\nnicotine market. According to Grand View Research\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4685825-1&h=962902256&u=https%3A%2F%2Fwww.grandviewresearch.com%2Findustry-analysis%2Fnicotine-pouches-market-report&a=Grand+View+Research)\n, the nicotine pouch market was approximately $7 billion in 2025 and is\nprojected to grow at nearly 25% annually through 2033, potentially exceeding\n$40 billion.\n\n\"This joint venture represents a meaningful strategic expansion for Ispire,\"\nsaid Michael Wang, Co-Chief Executive Officer of Ispire. \"Nicotine pouches are\na major global growth category, and this partnership enables us to enter the\nmarket with immediate operational capability and pharmaceutical-grade\nmanufacturing expertise. Combined with our global distribution and regulatory\ninfrastructure, we believe this positions us to build a significant new\nrevenue stream and further advance our broader nicotine platform strategy.\"\n\nUnder the terms of the agreement, Jincheng Pharma will contribute\nmanufacturing equipment, technical expertise, and nicotine pouch materials,\nenabling a rapid operational ramp-up and supporting near-term production and\ncommercialization. The joint venture is expected to leverage Ispire's\nstrengths in precision dosing, regulatory compliance, and global distribution\nto differentiate its nicotine pouch offerings in an increasingly competitive\nmarket.\n\n\"Ispire's proven manufacturing excellence and global regulatory capabilities\naccelerate our path to commercialization,\" said Jiaquan Li, Chairman and\nPresident of Jincheng Pharma. \"By combining our pharmaceutical expertise and\ncustomer relationships with Ispire's operational capabilities, we are well\npositioned to scale high-quality nicotine pouch production quickly and\nresponsibly.\"\n\nJincheng Pharma is a diversified pharmaceutical company with approximately\n3,800 employees and more than 30 affiliated companies worldwide. The company\nis engaged in the research, development, production, and commercialization of\npharmaceutical intermediates, active pharmaceutical ingredients (APIs),\nfinished pharmaceutical products, and health-related products.\n\nJincheng selected Ispire as its partner based on Ispire's reputation for\nhigh-quality manufacturing, operational execution, and strong global\nregulatory compliance infrastructure.\n\nThe Company expects initial production to be supported by existing commercial\nrelationships and intends to pursue additional business development\nopportunities within the oral nicotine segment as part of its broader\ninternational nicotine platform strategy.\n\nThis expansion builds on Ispire's ongoing efforts to diversify its product\nportfolio across multiple reduced-risk nicotine formats while leveraging its\nmanufacturing scale, compliance capabilities, and global distribution network.\n\nAbout Ispire Technology Inc.\nIspire is engaged in the research and development, design, commercialization,\nsales, marketing and distribution of branded e-cigarettes and cannabis vaping\nproducts. The Company's operating subsidiaries own or license more than 400\npatents worldwide. Ispire's branded e-cigarette products are marketed under\nthe Aspire name and are sold worldwide (except in the U.S., People's Republic\nof China and Russia) primarily through its global distribution network. The\nCompany also engages in original design manufacture (ODM) relationships with\ne-cigarette brands and retailers worldwide. The Company's cannabis products\nare marketed under the Ispire brand name primarily on an ODM basis to other\ncannabis vapor companies. Ispire sells its cannabis vaping hardware in the US,\nEurope and South Africa and it recently commenced marketing activities and\ncustomer engagement in Canada and Latin America. For more information, visit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4685825-1&h=2050832597&u=http%3A%2F%2Fwww.ispiretechnology.com%2F&a=%C2%A0)\nwww.ispiretechnology.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4685825-1&h=3574568751&u=http%3A%2F%2Fwww.ispiretechnology.com%2F&a=www.ispiretechnology.com)\nor follow Ispire on\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4685825-1&h=57531690&u=https%3A%2F%2Fwww.instagram.com%2Fgetispire%2F&a=%C2%A0)\nInstagram\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4685825-1&h=4178055008&u=https%3A%2F%2Fwww.instagram.com%2Fgetispire%2F&a=Instagram)\n,\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4685825-1&h=844070382&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fgetispire%2F&a=%C2%A0)\nLinkedIn\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4685825-1&h=955706779&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fgetispire%2F&a=LinkedIn)\n,\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4685825-1&h=248433898&u=https%3A%2F%2Ftwitter.com%2Fgetispire&a=%C2%A0)\nTwitter\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4685825-1&h=554039776&u=https%3A%2F%2Ftwitter.com%2Fgetispire&a=Twitter)\nand YouTube\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4685825-1&h=1649412600&u=https%3A%2F%2Fwww.youtube.com%2Fchannel%2FUC6X18XH9tLQFLee9gPPbaxA&a=%C2%A0YouTube)\n.\n\nForward Looking Statements\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended (\"Securities Act\") as\nwell as Section 21E of the Securities Exchange Act of 1934, as amended, and\nthe Private Securities Litigation Reform Act of 1995, as amended, that are\nintended to be covered by the safe harbor created by those sections.\nForward-looking statements, which are based on certain assumptions and\ndescribe the Company's future plans, strategies and expectations, can\ngenerally be identified by the use of forward-looking terms such as \"believe,\"\n\"expect,\" \"may,\" \"will,\" \"should,\" \"would,\" \"could,\" \"seek,\" \"intend,\" \"plan,\"\n\"goal,\" \"project,\" \"estimate,\" \"anticipate,\" \"strategy,\" \"future,\" \"likely\" or\nother comparable terms, although not all forward-looking statements contain\nthese identifying words. All statements other than statements of historical\nfacts included in this press release regarding the Company's strategies,\nprospects, financial condition, operations, costs, plans and objectives are\nforward-looking statements. Important factors that could cause the Company's\nactual results and financial condition to differ materially from those\nindicated in the forward-looking statements. Such forward-looking statements\ninclude, but are not limited to, risks and uncertainties including those\nregarding: whether the Company may be successful in re-entering the U.S. ENDS\nmarket; the approval or rejection of any PMTA submitted by the Company;\nwhether the Company will be successful in its plans to further expand into the\nAfrican market; whether the Company's joint venture with Touch Point Worldwide\nInc. d/b/a/ Berify and Chemular Inc. (the \"Joint Venture\") may be successful\nin achieving its goals as currently contemplated, with different terms, or at\nall; the Joint Venture's ability to innovate in the e-cigarette technology\nspace or develop age gating or age verification technologies for nicotine\nvaping devices; the Company's ability to collect its accounts receivable in a\ntimely manner; the Company's business strategies; the ability of the Company\nto market to the Ispire ONE™; Ispire ONE™'s success in meeting its goals;\nthe ability of its customers to derive the anticipated benefits of the Ispire\nONE™ and the success of its products on the markets; the Ispire ONE™\nproving to be safe; and the risk and uncertainties described in \"Risk\nFactors,\" \"Management's Discussion and Analysis of Financial Condition and\nResults of Operations,\" \"Cautionary Note on Forward-Looking Statements\" and\nthe additional risk described in Ispire's Annual Report on Form 10-K for the\nyear ended June 30, 2025 and any subsequent filings which Ispire makes with\nthe SEC. You should not rely upon forward-looking statements as predictions of\nfuture events. The forward-looking statements made in this press release\nrelate only to events or information as of the date on which the statements\nare made in this press release. We undertake no obligation to update or revise\nany forward-looking statements, whether as a result of new information, future\nevents or otherwise, after the date on which the statements are made or to\nreflect the occurrence of unanticipated events except as required by\napplicable law. You should read this press release with the understanding that\nour actual future results may be materially different from what we expect.\n\nIR Contact:\nBrett Maas\nHayden IR\n(646) 536-7331\nbrett@haydenir.com (mailto:brett@haydenir.com)\n\nJames Carbonara\nHayden IR\n(646)-755-7412\njames@haydenir.com (mailto:james@haydenir.com)\n\nPR Contact:\nEllen Mellody\n+1-570-209-2947\nispire@kcsa.com (mailto:ispire@kcsa.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/ispire-technology-expands-into-high-growth-nicotine-pouch-market-through-strategic-joint-venture-with-jincheng-pharma-302768974.html\n(https://www.prnewswire.com/news-releases/ispire-technology-expands-into-high-growth-nicotine-pouch-market-through-strategic-joint-venture-with-jincheng-pharma-302768974.html)\n\nSOURCE Ispire Technology Inc.\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2771569/Ispire_Technology_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn9WFT6Ka","title":"Ispire Technology Expands Into High-Growth Nicotine Pouch Market Through Strategic Joint Venture with Jincheng Pharma","author":"PR Newswire","ticker":"ISPR","created":"2026-05-12T12:30:02.562Z","tickers":["ISPR"],"exchange":"NASDAQ","article_body":"Ispire Technology Expands Into High-Growth Nicotine Pouch Market Through Strategic Joint Venture with Jincheng Pharma\n\nPR Newswire\n\nLOS ANGELES, May 12, 2026\n\nPartnership combines pharmaceutical-grade manufacturing with Ispire's global\nplatform to accelerate entry into one of the fastest-growing nicotine segments\n\nLOS ANGELES, May 12, 2026 /PRNewswire/ -- Ispire Technology Inc.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4685825-1&h=609010424&u=https%3A%2F%2Fispiretechnology.com%2F&a=Ispire+Technology+Inc.)\n(\"Ispire\" or the \"Company\") (NASDAQ: ISPR\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4685825-1&h=3905662850&u=https%3A%2F%2Fwww.nasdaq.com%2Fmarket-activity%2Fstocks%2Fispr&a=NASDAQ%3A+ISPR)\n), a trailblazer in vaping technology and precision dosing, announced that it\nhas entered into a joint venture with Shandong Jincheng Pharmaceutical Group\nCo., Ltd.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4685825-1&h=3130007742&u=http%3A%2F%2Fwww.jinchengpharm.com%2Fwap_index_en.html&a=Shandong+Jincheng+Pharmaceutical+Group+Co.%2C+Ltd.)\n(SZSE: 300233) (\"Jincheng Pharma\"), a global pharmaceutical company, to\nmanufacture and commercialize nicotine pouch products.\n\n(https://mma.prnewswire.com/media/2771569/Ispire_Technology_Logo.html)\n\nThe joint venture marks Ispire's entry into the rapidly expanding oral\nnicotine category, broadening its portfolio beyond vaping hardware and\npositioning the Company in one of the fastest-growing segments of the global\nnicotine market. According to Grand View Research\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4685825-1&h=962902256&u=https%3A%2F%2Fwww.grandviewresearch.com%2Findustry-analysis%2Fnicotine-pouches-market-report&a=Grand+View+Research)\n, the nicotine pouch market was approximately $7 billion in 2025 and is\nprojected to grow at nearly 25% annually through 2033, potentially exceeding\n$40 billion.\n\n\"This joint venture represents a meaningful strategic expansion for Ispire,\"\nsaid Michael Wang, Co-Chief Executive Officer of Ispire. \"Nicotine pouches are\na major global growth category, and this partnership enables us to enter the\nmarket with immediate operational capability and pharmaceutical-grade\nmanufacturing expertise. Combined with our global distribution and regulatory\ninfrastructure, we believe this positions us to build a significant new\nrevenue stream and further advance our broader nicotine platform strategy.\"\n\nUnder the terms of the agreement, Jincheng Pharma will contribute\nmanufacturing equipment, technical expertise, and nicotine pouch materials,\nenabling a rapid operational ramp-up and supporting near-term production and\ncommercialization. The joint venture is expected to leverage Ispire's\nstrengths in precision dosing, regulatory compliance, and global distribution\nto differentiate its nicotine pouch offerings in an increasingly competitive\nmarket.\n\n\"Ispire's proven manufacturing excellence and global regulatory capabilities\naccelerate our path to commercialization,\" said Jiaquan Li, Chairman and\nPresident of Jincheng Pharma. \"By combining our pharmaceutical expertise and\ncustomer relationships with Ispire's operational capabilities, we are well\npositioned to scale high-quality nicotine pouch production quickly and\nresponsibly.\"\n\nJincheng Pharma is a diversified pharmaceutical company with approximately\n3,800 employees and more than 30 affiliated companies worldwide. The company\nis engaged in the research, development, production, and commercialization of\npharmaceutical intermediates, active pharmaceutical ingredients (APIs),\nfinished pharmaceutical products, and health-related products.\n\nJincheng selected Ispire as its partner based on Ispire's reputation for\nhigh-quality manufacturing, operational execution, and strong global\nregulatory compliance infrastructure.\n\nThe Company expects initial production to be supported by existing commercial\nrelationships and intends to pursue additional business development\nopportunities within the oral nicotine segment as part of its broader\ninternational nicotine platform strategy.\n\nThis expansion builds on Ispire's ongoing efforts to diversify its product\nportfolio across multiple reduced-risk nicotine formats while leveraging its\nmanufacturing scale, compliance capabilities, and global distribution network.\n\nAbout Ispire Technology Inc.\nIspire is engaged in the research and development, design, commercialization,\nsales, marketing and distribution of branded e-cigarettes and cannabis vaping\nproducts. The Company's operating subsidiaries own or license more than 400\npatents worldwide. Ispire's branded e-cigarette products are marketed under\nthe Aspire name and are sold worldwide (except in the U.S., People's Republic\nof China and Russia) primarily through its global distribution network. The\nCompany also engages in original design manufacture (ODM) relationships with\ne-cigarette brands and retailers worldwide. The Company's cannabis products\nare marketed under the Ispire brand name primarily on an ODM basis to other\ncannabis vapor companies. Ispire sells its cannabis vaping hardware in the US,\nEurope and South Africa and it recently commenced marketing activities and\ncustomer engagement in Canada and Latin America. For more information, visit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4685825-1&h=2050832597&u=http%3A%2F%2Fwww.ispiretechnology.com%2F&a=%C2%A0)\nwww.ispiretechnology.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4685825-1&h=3574568751&u=http%3A%2F%2Fwww.ispiretechnology.com%2F&a=www.ispiretechnology.com)\nor follow Ispire on\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4685825-1&h=57531690&u=https%3A%2F%2Fwww.instagram.com%2Fgetispire%2F&a=%C2%A0)\nInstagram\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4685825-1&h=4178055008&u=https%3A%2F%2Fwww.instagram.com%2Fgetispire%2F&a=Instagram)\n,\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4685825-1&h=844070382&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fgetispire%2F&a=%C2%A0)\nLinkedIn\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4685825-1&h=955706779&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fgetispire%2F&a=LinkedIn)\n,\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4685825-1&h=248433898&u=https%3A%2F%2Ftwitter.com%2Fgetispire&a=%C2%A0)\nTwitter\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4685825-1&h=554039776&u=https%3A%2F%2Ftwitter.com%2Fgetispire&a=Twitter)\nand YouTube\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4685825-1&h=1649412600&u=https%3A%2F%2Fwww.youtube.com%2Fchannel%2FUC6X18XH9tLQFLee9gPPbaxA&a=%C2%A0YouTube)\n.\n\nForward Looking Statements\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended (\"Securities Act\") as\nwell as Section 21E of the Securities Exchange Act of 1934, as amended, and\nthe Private Securities Litigation Reform Act of 1995, as amended, that are\nintended to be covered by the safe harbor created by those sections.\nForward-looking statements, which are based on certain assumptions and\ndescribe the Company's future plans, strategies and expectations, can\ngenerally be identified by the use of forward-looking terms such as \"believe,\"\n\"expect,\" \"may,\" \"will,\" \"should,\" \"would,\" \"could,\" \"seek,\" \"intend,\" \"plan,\"\n\"goal,\" \"project,\" \"estimate,\" \"anticipate,\" \"strategy,\" \"future,\" \"likely\" or\nother comparable terms, although not all forward-looking statements contain\nthese identifying words. All statements other than statements of historical\nfacts included in this press release regarding the Company's strategies,\nprospects, financial condition, operations, costs, plans and objectives are\nforward-looking statements. Important factors that could cause the Company's\nactual results and financial condition to differ materially from those\nindicated in the forward-looking statements. Such forward-looking statements\ninclude, but are not limited to, risks and uncertainties including those\nregarding: whether the Company may be successful in re-entering the U.S. ENDS\nmarket; the approval or rejection of any PMTA submitted by the Company;\nwhether the Company will be successful in its plans to further expand into the\nAfrican market; whether the Company's joint venture with Touch Point Worldwide\nInc. d/b/a/ Berify and Chemular Inc. (the \"Joint Venture\") may be successful\nin achieving its goals as currently contemplated, with different terms, or at\nall; the Joint Venture's ability to innovate in the e-cigarette technology\nspace or develop age gating or age verification technologies for nicotine\nvaping devices; the Company's ability to collect its accounts receivable in a\ntimely manner; the Company's business strategies; the ability of the Company\nto market to the Ispire ONE™; Ispire ONE™'s success in meeting its goals;\nthe ability of its customers to derive the anticipated benefits of the Ispire\nONE™ and the success of its products on the markets; the Ispire ONE™\nproving to be safe; and the risk and uncertainties described in \"Risk\nFactors,\" \"Management's Discussion and Analysis of Financial Condition and\nResults of Operations,\" \"Cautionary Note on Forward-Looking Statements\" and\nthe additional risk described in Ispire's Annual Report on Form 10-K for the\nyear ended June 30, 2025 and any subsequent filings which Ispire makes with\nthe SEC. You should not rely upon forward-looking statements as predictions of\nfuture events. The forward-looking statements made in this press release\nrelate only to events or information as of the date on which the statements\nare made in this press release. We undertake no obligation to update or revise\nany forward-looking statements, whether as a result of new information, future\nevents or otherwise, after the date on which the statements are made or to\nreflect the occurrence of unanticipated events except as required by\napplicable law. You should read this press release with the understanding that\nour actual future results may be materially different from what we expect.\n\nIR Contact:\nBrett Maas\nHayden IR\n(646) 536-7331\nbrett@haydenir.com (mailto:brett@haydenir.com)\n\nJames Carbonara\nHayden IR\n(646)-755-7412\njames@haydenir.com (mailto:james@haydenir.com)\n\nPR Contact:\nEllen Mellody\n+1-570-209-2947\nispire@kcsa.com (mailto:ispire@kcsa.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/ispire-technology-expands-into-high-growth-nicotine-pouch-market-through-strategic-joint-venture-with-jincheng-pharma-302768974.html\n(https://www.prnewswire.com/news-releases/ispire-technology-expands-into-high-growth-nicotine-pouch-market-through-strategic-joint-venture-with-jincheng-pharma-302768974.html)\n\nSOURCE Ispire Technology Inc.\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2771569/Ispire_Technology_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-05-12T12:30:02.61260855Z","server_sent_at_ms":1778589002612},"received_at":"2026-05-12T12:30:02.841Z","source_url":"https://www.prnewswire.com/news-releases/ispire-technology-expands-into-high-growth-nicotine-pouch-market-through-strategic-joint-venture-with-jincheng-pharma-302768974.html"},"analysis":null,"durationMs":null,"modelName":null}}